A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal women.

Gynecol EndocrinolApr 24, 2026 (epub)
Clinical ResearchEndocrinologyObstetrics & Gynecology

Lili Liu, Xiangyan Ruan, Muqing Gu et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of Gushukang on bone mineral density (BMD) in 156 perimenopausal and postmenopausal women. After 6 months, the combination therapy group showed a significant increase in BMD compared to baseline (p < 0.01), while hormone therapy also improved BMD but to a lesser extent.

Key findings

  • The combination therapy group had a significant increase in BMD after 6 months (p < 0.01).
  • FSH and LH levels decreased significantly in the hormone therapy and combination groups (p < 0.05).
  • E2 levels increased significantly in the hormone therapy and combination groups (p < 0.05).
  • No significant differences in liver or kidney function were found in any group.

Why it matters

The study highlights the potential of Gushukang and hormone therapy in improving bone mineral density in women undergoing menopause, which is crucial for preventing osteoporosis and related fractures.

Source

PubMed · PMID 42033017

Published in Gynecol Endocrinol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.